DK2683826T3 - Anvendelse af aptamerer til behandling og/eller diagnosticering af autoimmune sygdomme - Google Patents

Anvendelse af aptamerer til behandling og/eller diagnosticering af autoimmune sygdomme Download PDF

Info

Publication number
DK2683826T3
DK2683826T3 DK12711799.2T DK12711799T DK2683826T3 DK 2683826 T3 DK2683826 T3 DK 2683826T3 DK 12711799 T DK12711799 T DK 12711799T DK 2683826 T3 DK2683826 T3 DK 2683826T3
Authority
DK
Denmark
Prior art keywords
aptamer
receptor
cardiomyopathy
chagas
seq
Prior art date
Application number
DK12711799.2T
Other languages
English (en)
Inventor
Ingolf Schimke
Annekathrin Haberland
Gerd Wallukat
Original Assignee
Charité Universitätsmedizin Berlin
Max-Delbrück-Centrum für Molekulare Medizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité Universitätsmedizin Berlin, Max-Delbrück-Centrum für Molekulare Medizin filed Critical Charité Universitätsmedizin Berlin
Application granted granted Critical
Publication of DK2683826T3 publication Critical patent/DK2683826T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)

Claims (11)

1. Aptamer omfattende en nukleinsyresekvens med SEQ ID No. 1, SEQ ID No.2, SEQ ID No. 3 og/eller en nukleinsyresekvens, der er mindst 80 % identisk med en af SEQ ID No. 1,2 og 3, til anvendelse ved behandling af autoimmune sygdomme ved indgriben i interaktionen af autoantistoffer, der er specifikke for G-protein-koblede receptorer forbundet med autoimmune sygdomme, hvor den autoimmune sygdom er kardiomyopati, dilateret kardiomy-opati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaøsofagus, Chagas' neuropati, godartet prostatahyperplasi, sklerodermi, psoriasis, Raynaud's syndrom, præeklampsi, nyre-allograft-afstødning, myocarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension og/eller Alzheimers sygdom, og hvor aptameren binder specifikt og med høj affinitet til antiautostofferne.
2. Aptamer omfattende eller bestående af nukleinsyresekvensen med SEQ ID No. 1, SEQ ID No.2, SEQ ID No. 3 og/eller en nukleinsyresekvens, der er mindst 80 % identisk med en af SEQ ID No. 1,2 og 3, til anvendelse ifølge krav 1, hvor aptameren er til anvendelse som selektiv ingrediens under terapeutisk aferese af blod eller bestanddele deraf fra en patient, der lider af en autoimmun sygdom forbundet med tilstedeværelsen af autoantistoffer, der er specifikke for en G-protein-koblet receptor, hvor autoantistofferne er til stede i serum fra en patient, der lider af den autoimmune sygdom, hvor den autoimmune sygdom er kardiomyopati, dilateret kardiomyopati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaøsofagus, Chagas' neuropati, godartet prostatahyperplasi, sklerodermi, psoriasis, Raynaud's syndrom, præeklampsi, nyre-allograft-afstødning, myocarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension og/eller Alzheimers sygdom.
3. Aptamer til anvendelse ifølge krav 1 eller 2, hvor aptameren anvendes i behandling af et menneske.
4. Aptamer til anvendelse ifølge et af de foregående krav, hvor aptameren er en DNA-aptamer.
5. Aptamer til anvendelse ifølge et af de foregående krav, hvor aptameren består af nukleinsyresekvensen med SEQ ID No. 1, SEQ ID No.2, SEQ ID No. 3 eller en nukleinsyresekvens, der er mindst 80 % identisk med en af SEQ ID No. 1,2 og 3.
6. Farmaceutisk sammensætning omfattende en aptamer ifølge et af kravene 1 til 5 og mindst et farmaceutisk acceptabelt hjælpestof, til anvendelse ved behandling af autoimmune sygdomme ved indgriben i interaktionen af autoantistoffer, der er specifikke for G-protein-koblede receptorer forbundet med autoimmune sygdomme, hvor den autoimmune sygdom er kardiomyopati, dilateret kardiomyopati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' me-gaosofagus, Chagas' neuropati, godartet prostatahyperplasi, sklerodermi, psoriasis, Raynaud's syndrom, præeklampsi, nyre-allograft-afstodning, myocarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension og/eller Alzheimers sygdom.
7. Kit omfattende mindst en aptamer ifølge et af kravene 1 til 5 og en beholder, til anvendelse ved behandling af autoimmune sygdomme ved indgriben i interaktionen af autoantistoffer, der er specifikke for G-protein-koblede receptorer forbundet med autoimmune sygdomme, hvor den autoimmune sygdom er kardiomyopati, dilateret kardiomyopati (DCM), peripartum kardiomyopati (PPCM), idiopatisk kardiomyopati, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaøsofagus, Chagas' neuropati, godartet prostatahyperplasi, sklerodermi, psoriasis, Raynaud's syndrom, præeklampsi, nyre-allograft-afstodning, myocarditis, glaukom, hypertension, pulmonal hypertension, malign hypertension og/eller Alzheimers sygdom.
8. Anvendelse af en aptamer ifølge et af kravene 1 til 5 til in vitro detektering af et antistof, der er specifikt for en G-protein-koblet receptor, fortrinsvis den humane G-protein-koblede receptor adrenerg alfa-1 -receptor, adrenerg beta-1-receptor, adrenerg beta-2-receptor, endothelin 1 ETA-receptor, muskarin M2-receptor, angiotensin II AT1-receptor og/eller PAR-receptorer.
9. Anvendelse ifølge krav 8, hvor antistoffet, der skal detekteres, er et autoantistof.
10. Anvendelse ifølge krav 8 eller 9, hvor antistoffet er til stede i eller stammer fra en kropsvæske, fortrinsvis en væske fra en menneskekrop, mere fortrinsvis humant blod, plasma, serum, urin, fæces, synovialvæske, interstitiel væske, lymfe, spyt, spinalvæske og/eller tårevæske.
11. Anvendelse ifølge krav 10, hvor kropsvæsken udtages fra en person, der lider af eller mistænkes for at lide af en autoimmun sygdom, fortrinsvis en autoimmun sygdom forbundet med tilstedeværelse i serum hos patienten af autoantistoffer, der er specifikke for en G-protein-koblet receptor, mere fortrinsvis autoimmune sygdomme forbundet med tilstedeværelse i serum hos patienten af autoantistoffer, der er specifikke for adrenerg alpha-1 -receptor, adrenerg beta-1-receptor, adrenerg beta-2-receptor, endothelin 1 ETA-receptor, muskarin M2-receptor, angiotensin II AT1-receptor og/eller PAR-receptorer.
DK12711799.2T 2011-03-07 2012-03-02 Anvendelse af aptamerer til behandling og/eller diagnosticering af autoimmune sygdomme DK2683826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449772P 2011-03-07 2011-03-07
EP11157229A EP2497828A1 (en) 2011-03-07 2011-03-07 Use of aptamers in therapy and/or diagnosis of autoimmune diseases
PCT/EP2012/053616 WO2012119938A2 (en) 2011-03-07 2012-03-02 Use of aptamers in therapy and/or diagnosis of autoimmune diseases

Publications (1)

Publication Number Publication Date
DK2683826T3 true DK2683826T3 (da) 2016-09-05

Family

ID=44223589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12711799.2T DK2683826T3 (da) 2011-03-07 2012-03-02 Anvendelse af aptamerer til behandling og/eller diagnosticering af autoimmune sygdomme

Country Status (11)

Country Link
US (3) US9234201B2 (da)
EP (3) EP2497828A1 (da)
JP (5) JP6190276B2 (da)
CN (4) CN109172594A (da)
AU (1) AU2012224729B2 (da)
BR (1) BR112013022883B1 (da)
CA (1) CA2828896C (da)
DK (1) DK2683826T3 (da)
ES (1) ES2589796T3 (da)
PL (1) PL2683826T3 (da)
WO (1) WO2012119938A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP3011974B1 (en) 2011-06-02 2018-08-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
CN103728454B (zh) * 2012-10-10 2016-05-18 吴庄民 基于表位抗原肽的抗内皮素受体a抗体酶联免疫试剂盒及其应用
EP2982756A1 (en) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
JP6793917B2 (ja) * 2016-08-15 2020-12-02 国立大学法人東京農工大学 アプタマー及び抗体検出方法
EP3845650A1 (en) * 2016-11-23 2021-07-07 Berlin Cures GmbH Aptamers for use in inhibition and/or suppression of tlr9 activation
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
JP2023542389A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
CN113109571B (zh) * 2021-03-19 2023-05-05 浙江工商大学 一种用于评估个体过敏程度的试剂盒
CN113075400B (zh) * 2021-03-29 2022-07-22 广州市妇女儿童医疗中心 抗双链dna抗体作为先天性巨结肠诊断标志物的应用
CA3214646A1 (en) * 2021-04-09 2022-10-13 Annekathrin Haberland Aptamers for use in the treatment of coronaviridae infections
JP7359457B2 (ja) * 2021-10-11 2023-10-11 タグシクス・バイオ株式会社 自己免疫性疾患治療薬
WO2024038918A1 (ja) * 2022-08-19 2024-02-22 国立大学法人東京農工大学 一本鎖抗体結合アプタマー

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
EP0572529A4 (en) * 1991-02-21 1994-11-02 Gilead Sciences Inc SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME.
IL101038A0 (en) * 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
WO1996008559A1 (en) * 1994-09-16 1996-03-21 Cardiac Crc Nominees Pty. Ltd. Glycosaminoglycan-degrading enzyme inhibition and resultant disease therapies
DE10041560A1 (de) * 2000-08-24 2002-03-07 Max Delbrueck Centrum Peptide des alpha1-adrenergen Rezeptors und ihre Verwendung bei Psoriasis
WO2002026932A2 (en) * 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
DE10311106B4 (de) * 2003-01-31 2011-05-05 Max-Delbrück-Centrum für Molekulare Medizin Peptide gegen Kälteunverträglichkeit hervorrufende Autoantikörper, dafür kodierende Nukleinsäuren, ihre Verwendung und diese umfassende pharmazeutische Zusammensetzungen
DE10355702A1 (de) * 2003-06-12 2005-01-13 Kübler, Ulrich, Dr. Methode zur Diagnose und Therapie von Gliomen und Astrozytomen in einem sehr frühen Stadium
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
WO2005037323A2 (en) * 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
CN101501056A (zh) * 2005-08-26 2009-08-05 阿切米克斯公司 以高亲和力结合凝血酶的适体
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
EP1832600A1 (en) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides against autoantibodies associated with glaucoma and use of these peptides
EP2080519A1 (en) * 2008-01-15 2009-07-22 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Peptides having binding affinity to an antibody which recognizes an epitope on an alpha1 loop 2 or beta 2 loop 1 of an adrenoreceptor
US8877177B2 (en) * 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
US20110275701A1 (en) 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases

Also Published As

Publication number Publication date
JP2023038284A (ja) 2023-03-16
EP2683826B1 (en) 2016-06-08
EP2497828A1 (en) 2012-09-12
BR112013022883B1 (pt) 2021-10-13
CA2828896C (en) 2019-02-19
PL2683826T3 (pl) 2017-01-31
JP2021100408A (ja) 2021-07-08
CN103608456B (zh) 2018-08-07
CN103608456A (zh) 2014-02-26
JP2019134709A (ja) 2019-08-15
ES2589796T3 (es) 2016-11-16
CN109106722B (zh) 2023-05-30
JP7125370B2 (ja) 2022-08-24
US9234201B2 (en) 2016-01-12
CN116298268A (zh) 2023-06-23
EP3085786A2 (en) 2016-10-26
US9862953B2 (en) 2018-01-09
EP3085786A3 (en) 2016-11-30
EP2683826A2 (en) 2014-01-15
CN109106722A (zh) 2019-01-01
US20160160218A1 (en) 2016-06-09
JP6550092B2 (ja) 2019-07-24
AU2012224729A1 (en) 2013-10-24
BR112013022883A2 (pt) 2016-12-06
WO2012119938A2 (en) 2012-09-13
WO2012119938A3 (en) 2012-11-22
AU2012224729B2 (en) 2016-09-22
US20180127757A1 (en) 2018-05-10
US10266830B2 (en) 2019-04-23
JP6190276B2 (ja) 2017-08-30
JP2017153479A (ja) 2017-09-07
CA2828896A1 (en) 2012-09-13
US20140155466A1 (en) 2014-06-05
JP2014509849A (ja) 2014-04-24
CN109172594A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
US10266830B2 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
JP7267689B2 (ja) 自己抗体関連疾患に対する使用のためのアプタマー
EP2588115B1 (en) Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta-1-adrenergic receptor
WO2008059877A1 (fr) Aptamère contre la midkine et son utilisation
KR20230170931A (ko) 코로나바이러스 감염 치료에 사용하기 위한 압타머
WO2019222344A1 (en) Stem-loop compositions and methods for inhibiting interleukin-8